

CURRICULUM VITAE

ROBERT M. NARAGHI, M.D.

2200 West Third Street, Suite 500 Los Angeles, CA 90057
Tel: (213) 207-5711 Fax: (213) 413-0190
robnaraghi@yahoo.com

A. CURRENT APPOINTMENTS

2006—Present	Medical Director Kidney and Pancreas Transplantation Multi Organ Transplant Center St. Vincent Medical Center, Los Angeles, CA 90057
2011—2015	President & CEO Transplant Research Institute, Inc. Los Angeles, CA 90057
2006—2009	Pediatric Kidney Transplant Surgeon Children's Hospital Los Angeles
2007—2009	Clinical Assistant Professor of Urology (Voluntary) Keck School of Medicine, University of Southern California

B. EDUCATION

Undergraduate:	University of Southern California Los Angeles, California 90033 Bachelor of Science	1983 - 1987
Graduate:	University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania 15213	1987 - 1989
	University of Southern California Los Angeles, California 90033 Medical Degree	1989 - 1991
Postgraduate:	University of Pittsburgh Presbyterian Hospital	1991 - 1993

General Surgery

University of Pittsburgh
Presbyterian Hospital
Urological Surgery
1993 – 1997

Fellowship:

University of Southern California
St. Vincent Medical Center
Renal and Pancreas Transplantation
Vascular Access Surgery
1997 – 1998

Private Practice

Mendez Transplant & Urological Medical Group, Inc.
2200 W. Third Street, Suite 500
Los Angeles, California 90057
1998 - 2006

ISIS Urologic & Transplant Inst. Inc.
2200 W. Third Street, Suite 300
Los Angeles, California 90057
2006 – 2010

C. CERTIFICATION AND LICENSURE

Medical Surgeon, Physician
Medical Surgeon, Physician
American Board of Urology
B.N.D.D.

State of California, # G83950
Commonwealth of Pennsylvania, # MD-051218-L
Board Certified -- 2003
BN4056328

D. AWARDS

First Prize

Pittsburgh Urological Association
Resident Essay Competition
Clinical
1994

Second Prize

Pittsburgh Urological Association
Resident Essay Competition
Basic Research
1995

**Young Investigator
Award**

American Society of Transplant Physicians
15th Annual Scientific Meeting
Dallas, Texas
1996

**Transplant Society
Travel Award**

XVI International Congress
of the Transplantation Society
Barcelona, Spain
1996

**Outstanding Chief
Resident Award**

University of Pittsburgh
Urological Surgery

Dr. Thomas Hakala

**Pfizer Scholars in
Urology Award**

University of Pittsburgh

1997

GRANT – RESEARCH STUDY

Hispanic Living Donation: Kidney Health Literacy and Education Intervention.
HRSA (Health Resources and Services Administration) Grant; Deborah Maurer, Principal Investigator, Robert Naraghi, Medical Director Advisor; Eusebio Alvaro, Principal Research/Evaluator, Jason T. Siegel, Medical Director Advisor 08/01/2007—07/31/2010

BIBLIOGRAPHY

PUBLISHED ABSTRACTS AND PRESENTATIONS

World Transplant Congress Annual Meeting, San Francisco, CA, July 26-30, 2014.

Genetic Variations in a Sestrin2/Sestrin3/mTOR Axis and Development of New-Onset Diabetes After Transplantation. Vu D, Shah T, Manzoor H, Hutchinson I, Lemp NA, Qazi YA, Ciccirelli JC, **Naraghi R**, Min DI. Poster of Distinction.

Relationship between Interleukin-2 Polymorphism and BK Virus Infection after Kidney Transplantation. Vu D, Shah T, Manzoor H, Hutchinson I, Lemp NA, Qazi YA, Ciccirelli JC, **Naraghi R**, Min DI. Poster of Distinction.

Impact of Inhibitor kappa B-alpha (I κ B- α) promoter polymorphisms on the risk of cytomegalovirus infection among Hispanic renal transplant recipients. Vu D, Shah T, Chiang E, Hutchinson I, **Naraghi R**, Min DI. Poster of Distinction.

ACCP Annual Meeting, New Mexico, 2013.

Interferon-gamma gene polymorphism +874 A/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients. Vu D, Shah T, **Naraghi R**, Hutchinson I, Min D.

Genetic Variations in a Sestrin2/Sestrin3/mTOR Axis and Development of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients. Vu D, Shah T, **Naraghi R**, Hutchinson I, Min D.

Relationship between Interleukin-2 Polymorphism and BK Virus Infection after Kidney Transplantation. Vu D, Shah T, **Naraghi R**, Hutchinson I, Min D.

American Society of Nephrology, Atlanta, GA, 2013.

Effect of Ciprofloxacin prophylaxis for BK virus Nephropathy in de novo kidney transplant patients. Shah T, Vu D, **Naraghi R**, Hutchinson I, Min D.

Intravenous immunoglobulin (IVIG) as a rescue therapy for BK Virus Nephropathy. Shah T, Vu D, **Naraghi R**, Hutchinson I, Min D.

American Transplant Congress, 2012

The impact of intravenous immunoglobulin in treatment for BK virus nephropathy. Don Vu, Tariq Shah, Robert Naraghi, Ian Hutchinson, David Min. Poster of Distinction. American Transplant Congress, 2012. Presented in “What’s Hot and What’s New Section”

Genetic polymorphisms of NF-kB and allograft survival after kidney transplantation in the Hispanic allograft recipients. E.Tellez-Corrales, T.Shah, I.Hutchinson, **R. Naraghi**, D.Min

XXIV International Congress of the Transplantation Society-Berlin, Germany, July 15th to 20th, 2012.

Association of Vitamin D Binding Protein Polymorphism With Long-Term Kidney Allograft Survival in Hispanic Kidney Transplant Recipients. Vu D, Shah T, **Naraghi R**, Hutchinson I, Min D.

Association of Interferon- γ and Tumor Necrosis Factor- α Cytokine Gene Polymorphisms with symptomatic BK virus infection. Vu D, Shah T, **Naraghi R**, Hutchinson I, Min D. (Oral presentation)

ACCP Annual Meeting Hollywood, FL October 21st-24th, 2012.

Impact of Cytokine Gene Polymorphisms on BK Virus Nephropathy in a Large Cohort of Kidney Transplant Recipients. Vu D, Sakharkar P, Shah T, **Naraghi R**, Hutchinson T, Min D. “Great Eight” (8 best papers) for overall Best Paper Presentation.

Intravenous immunoglobulin (IVIG) as a rescue therapy for BK Virus Nephropathy. Vu D, Shah T, **Naraghi R**, Hutchinson I, Min D.

American Society of Nephrology - Nov 8-13, 2005, Philadelphia, PA

“A Single Center Experience in Living Donor Renal Transplantation: A 3 yr. Analysis of Basiliximab vs. Non-Induction in 358 Recipients” G Ingle, T Shah, S Aswad, K Dudley, U Khetan, L Liang, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

“A Single-Center, 3-yr. Comparison of Basiliximab to Non-Induction Immunosuppression in 520 Deceased Donor Renal Transplant Patients” T Shah, G Ingle, S Aswad, T Bogaard, U Khetan, L Liang, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

“Efficacy and Tolerability of Myfortic vs CellCept in Living Kidney Transplantation Results of 6 Months Single Center Open Label Study” H Shidban, M Sabawi, M Puhawan, S Aswad, **R Naraghi**, L Liang, U Khetan, RG Mendez, R Mendez.

American Transplant Congress - May 21-25, 2005 - Seattle, Washington

“Induction Immunosuppression with Rabbit Antithymocyte Globulin or Basiliximab: A Single Center, 3 year Study in 432 Deceased Donor Renal Transplant Recipients” G Ingle, S Aswad, T Shah, K Dudley, U Khetan, L Liang, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

“A 5-year Analysis of Living Donor Renal Transplantation in Patients 70 years of Age and Older” T Shah, G Ingle, S Aswad, T Bogaard, U Khetan, L Liang, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

“A Single Center, 3 Year Evaluation of Rabbit Antithymocyte Globulin vs Basiliximab Induction in 128 Living Donor Renal Transplant Recipients” T Shah, S Aswad, G Ingle, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

A Single Center, 3 year Comparison of Basiliximab to Non Induction Immunosuppression in 520 Deceased Donor Renal Transplant Patients” T Shah, G Ingle, S Aswad, T Bogaard, U Khetan, L Liang, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

“Deceased Donor Renal Transplantation: A 5 year Follow-up of Recipients 70 Years of Age and Older” S Aswad, T Shah, G Ingle, T Bogaard, U Khetan, L Liang, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

“Thymoglobulin for Induction Therapy in Simultaneous Kidney and Pancreas Transplantation” **R Naraghi**, M Sabawi, K Karimzadeh, E Osorio, RG Mendez, R Mendez, H Shidban, S Aswad.

“A Single Center Experience in Living Donor Renal Transplantation: A 3 Year Analysis of Basiliximab vs Non Induction in 358 Recipients” G Ingle, T Shah, S Aswad, K Dudley, U Khetan, L Liang, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

Middle East Society of Organ Transplantation - Dec. 6-10, 2004 - Cairo, Egypt

“Uncontrolled Post-transplant Hypercholesterolemia Increases Morbidity and Mortality of Kidney Transplant Patients” S Aswad, H Shidban, **R Naraghi**, R Mendez and RG Mendez.

“Morbidity and Mortality of Transplanted Diabetic Patients vs Diabetic Patients Remaining on Dialysis” S Aswad, S Mirador, T Bogaard, RG Mendez, **R Naraghi**, and R Mendez.

“Risk Factors for Developing Post Transplant Diabetes Mellitus” S Aswad, **R Naraghi**, H Shidban, RG Mendez and R Mendez.

American Society of Nephrology Annual Meeting – Oct. 27– Nov. 1, 2004 – St. Louis, MO

“Diabetic Patients on Dialysis Should be Transplanted” S Aswad, U Khetan, **R Naraghi**,
RG
Mendez, R Mendez

“Post-transplant Anemia: High Incidence and Correlation with Graft Dysfunction from a Single
Center Study” H Shidban, R Mendez, T Bogaard, A Mehta, F Aswad, **R Naraghi** and S
Aswad.

XX International Congress of the Transplant Society - Sept. 5-10, 2004 - Vienna, Austria

“Diabetic Patients on Dialysis Should be Transplanted” S Aswad, U Khetan, **R Naraghi**,
RG
Mendez, R Mendez.

American Transplant Congress - May 15-19, 2004, Boston, MA

“Post-transplant Anemia: High Incidence and Correlation with Graft Dysfunction from a
Single
Center Study”, R Mendez, T Bogaard, A Mehta, F Aswad, **R Naraghi**, H Shidban and S
Aswad.

“Uncontrolled Post-transplant Hypercholesterolemia Increases Morbidity and Mortality
of
Kidney Transplant Patients” S Aswad, H Shidban, **R Naraghi**, R Mendez and RG Mendez.

“Morbidity and Mortality of Transplanted Diabetic Patients vs Diabetic Patients Remaining
on
Dialysis” S Aswad, S Mirador, T Bogaard, RG Mendez, **R Naraghi**, and R Mendez.

“Risk Factors for Developing Post Transplant Diabetes Mellitus” S Aswad, **R Naraghi**,
H
Shidban, RG Mendez and R Mendez.

American Society of Nephrology Annual Mtg. - Nov. 14-17, 2003, San Diego, CA

“Increased Incidence of Hypercholesterolemia in Renal Transplant Recipients
Receiving
Sirolimus” S Aswad, S Potter, H Shidban, **R Naraghi**, S Mirador, RG Mendez, R Mendez.

“Diversity of Hepatitis C Virus Hypervariable Region 1 Mutations Varies in Different
HCV
Positive Host Populations” S Aswad, L Corado, C Chinchilla, **R Naraghi**, H Shidban, R
Mendez, N Khan.

“Post-Transplant Complications of Simultaneous Pancreas-Kidney Transplantation: A
Single

Center Experience”, S Aswad, **R Naraghi**, H Shidban, RG Mendez, R Mendez.

“A Prospective, Randomized, Phase IV Comparative Trial of Thymoglobulin vs Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Transplant Recipients” S Aswad, H Shidban, **R Naraghi**, M Puhawan, M Sabawi, RG Mendez, R Mendez.

American Transplant Congress - May 30 – June 4, 2003 - Washington D.C.

“Minimally Invasive Live Donor (MILD) Nephrectomy via a 5-cm. Incision” **R Naraghi**, SR Potter, H Kon, E Mobley, A Aquino, H Shidban, S Beaudoin, Z Haddad, S Aswad and R Mendez.

“Post-transplant Complications of Simultaneous Pancreas-Kidney Transplantation: A Single Center Experience” S Aswad, **R Naraghi**, H Shidban, RG Mendez and R Mendez.

“Glomerulosclerosis on Frozen Biopsy and Clinical Outcome of Cadaveric Renal Transplants: A 3-Year Follow-up” **R. Naraghi**, A Aquino, S Aswad, H Shidban, RG Mendez and R Mendez.

“Six-month Results of the First Prospective, Randomized, Multi-Center Kidney Transplant Study Comparing Tacrolimus+Rapamune vs Tacrolimus+MMF Combination Therapy” R. Mendez for Fujisawa Study Group.

American Society of Nephrology - Oct. 30 – Nov. 4, 2002 - Philadelphia, PA

“Hepatitis B Infection (HBV) and Risk of Transmission from Hepatitis B (core) Antibody Positive Donor Kidneys in Renal Transplant Recipients” H. Shidban, S. Aswad, **R. Naraghi**, M. Sabawi, R.G. Mendez , R. Mendez.

XIX Intl. Congress of The Transplantation Society - Aug. 18-23, 2002 – Miami Beach, Florida

“Donor Glomerular Sclerosis Effect on Renal Transplant Outcome” S. Aswad, **R. Naraghi**, M Sabawi, H Shidban, D Tschirhart, SR Potter, T Mone, R Mendez.

American Urological Association Annual Mtg. – June 2-7, 2001 – Anaheim, CA

“Prospective Non Randomized Study Comparing Laparoscopic Donor Nephrectomy (LDN), Minimally Invasive Open Donor Nephrectomy (MIDN) and Open Donor

Nephrectomy (ODN): Recipient Outcome” I. Castillon-Vela, A Martinez, E Vapnek, G Nabieva, V Ayvazyan, H Shidban, T Bogaard, **R Naraghi**, R Mendez, RG Mendez.

“Anterior Retroperitoneal Open Donor Nephrectomy (ARODN)” I Castillon-Vela, P Asae, **R Naraghi**, T Bogaard, RG Mendez, R Mendez.

American Society of Transplantation – May 11-16, 2001 – Chicago, IL.

“Prospective Non Randomized Study Comparing Laparoscopic Donor Nephrectomy (LDN), Minimally Invasive Open Donor Nephrectomy (MIODN) and Open Donor Nephrectomy (ODN)” I Castillon-Vela, A Martinez, E Vapnek, V Ayvazyan, S Ayvazyan, G Nabieva, **R Naraghi**, R Mendez, RG Mendez.

“Laparoscopic Donor Nephrectomy (LDN): Initial Experience and Prospective Comparison with Open Donor Nephrectomy (ODN)” I Castillon-Vela, P Asai, A Martinez, J Llorente, E Vapnek, TP Bogaard, **R Naraghi**, R Mendez, RG Mendez.

“Minimally Invasive Open Donor Nephrectomy (MIODN)” I Castillon-Vela, R Naraghi, P Asai, S Aswad, U Khetan, AE DaSilva, RG Mendez, R. Mendez.

International Congress of Transplantation Society - August 27 – September 1, 2000 - Rome, Italy

“Muscle Splitting Donor Nephrectomy (MSDNx)” R.G. Mendez, I. Castillon-Vela, P. Asai, **R. Naraghi**, A. DaSilva, G. Chambers, T.P. Bogaard, R. Mendez.

“Controlled Trial of IL22R Antibody Basiliximab (Simulect) vs Low Dose OKT3 in Cadaver Kidney Transplant Recipients” R. Mendez, H. Shidban, M. Sabawi, S. Aswad, G. Chambers, I. Castillon, **R. Naraghi**, T. Bogaard, R.G. Mendez.

“Prospective Study Comparing Open Donor Nephrectomy (ODN), Minimally Invasive Open Donor Nephrectomy (MIDN) & Laparoscopic Donor Nephrectomy (LDN)” R.G. Mendez, I. Castillon-Vela, P. Asai, A. Martinez, J. Llorente, T.P. Bogaard, **R. Naraghi**, R. Mendez.

American Society of Transplantation – May 14-17, 2000 –Chicago, IL.

“Muscle Splitting Donor Nephrectomy: Analysis of 9 Cases and Comparison to Open Donor Nephrectomy”, I. Castillon-Vela, P. Asai, T.Bogaard, A. DaSilva, G. Chambers, **R. Naraghi**, R.G. Mendez, R. Mendez.

“Controlled Trial of IL2R Antibody Basiliximab (Simulect) vs Low Dose OKT3 in Cadaver Kidney Transplant Recipients” H. Shidban, M. Sabawi, S. Aswad, G. Chambers, I. Castillon, **R. Naraghi**, T.P. Bogaard, R.G. Mendez, R. Mendez.

“Muscle Splitting Donor Nephrectomy (MSDNx)” I. Castillon-Vela, P. Asai, **R. Naraghi**, A. DaSilva, G. Chambers, T.P. Bogaard, R.G. Mendez, R. Mendez.

“Prospective Non-randomized Study Comparing Open Donor Nephrectomy (ODN), Minimally Invasive Open Donor Nephrectomy (MIDN) and Laparoscopic Donor Nephrectomy (LDN)” I. Castillon-Vela, P. Asai A. Martinez, J. Llorente, T.P. Bogaard, **R. Naraghi**, R.G. Mendez, R. Mendez.

American Society of Transplant Physicians - May 15-19, 1999 - Chicago, IL

Renal Transplantation in Diabetic Patients: A Single Center Experience. S. Aswad, H. Shidban, **R. Naraghi**, R.G. Mendez, R. Mendez.

Naraghi, R., Smith, D., Shapiro, R., Vivas, C.A, Gritsch, H.A., Scantlebury, V.P., Randhawa, P, Demetris, A.J., Starzl, T.E., Fung, J., Jordan, M.L.**Long Term Follow-up of Tacrolimus Rescue Therapy for Renal Allograft Rejection.**XVI International Congress of the Transplantation Society. August, 1996

Jordan, M., **Naraghi, R.**, Shapiro, R., Smith, D., Vivas, C., Scantlebury, V., Gritsch, H., Randhawa, P., Demetris, A., Fung, J., Starzl, T.**Tacrolimus Rescue Therapy for Renal Allograft Rejection - Five Year Experience.** XVI International Congress of Transplantation Society. August, 1996.

Jordan, M.L., **Naraghi, R.**, Shapiro, R., Smith, D., Vivas, C.A., Scantlebury, V.P., Randhawa, P., Demetris, A.J., Fung, J.J., Starzl, T.E.

Tacrolimus Rescue Therapy for Renal Allograft Rejection - Five Year Experience.

American Society of Transplant Surgeons. 05/96

Naraghi, R., Smith, D., Shapiro, R., Vivas, C.A., Gritsch, H.A., Scantlebury, V.P., Randhawa, P., Demetris, A.J., Starzl, T.E., Fung, J., Jordan, M.L.**Long Term Follow-up of Tacrolimus Rescue Therapy for Renal Allograft Rejection.** American Society of Transplant Physicians. May, 1996.

Lyne, J.D., **Naraghi, R.M.**, Melhem, M.F., Finely, G.G., Wen, D., Liu, N., Deng, D., Salup, R.R.**Expression and Function of Neu Differentiation Factor and Its Receptor Proteins in Human Prostate Cancer Cells and Tissue.**

Proceedings of 1996 International Symposium on Biology of Prostate Growth, Washington, DC. 03/28/1996.

Lyne, J.C., **Naraghi, R.M.**, Melhem, M.A., Deng, D., Liu, N., Finley, G.G., Salup, R.R.

Human Prostate Cancer Cells Respond to But Do Not Secrete Neu Differentiation Factor

(NDF) in Spite of HER2/neu Gene Amplification and Protein Over Expression.

Proceedings of 86th Annual Meeting of the American Association for Cancer Research 36: 1234,1995.

Naraghi, R.M., Melhem, M.A., Deng, D., Finely, G.G., Sal R.R.

Human Prostate Cancer Cell Over Expression of Erb B2 May Be Due to HER2/neu Gene Amplification

Proceedings of the American Association for Cancer Research 36: 3838, 1995

AUA Northeastern Section Prior Annual Meeting Lake George, New York September, 1994

Routine Frozen Section of Pelvic Lymph Node Specimens to the Radical Retropubic

Prostatectomy Is Necessary in patients with Prostate Specific Antigen Levels Less Than 20 ng/ml

ACCR Annual Meeting Toronto, Canada 1995

Human Prostate Cancer Cell Over Expression of ErbB2 May Be Due to HER2/neu Gene

Amplification Human Prostate Cancer Cells Respond to But Do Not Secrete Neu Differentiation Factor (NDF) in Spite of HER2/neu Gene Amplification and Protein Over Expression

The Transplantation Society XVI International Congress 08/1996

Long Term Follow-up of Tacrolimus Rescue Therapy for Renal Allograft Rejection

Discovery Channel Live 2002: Kidney/Pancreas Transplantation

III International Meeting of Transplantation Barcelona, Spain December 15-16, 2003

“Minimally invasive donor Nephrectomy”

PUBLICATIONS:

Effects of mycophenolic acid on highly sensitized patients awaiting kidney transplant.

Shah T, Vu D, Corrales-Tellez E, Cicciarelli J, Hutchinson I, **Naraghi R**, Min DI. Transpl Immunol. 2013 Jan;28(1):32-7

Association between Granzyme B and Perforin I Polymorphisms and Allograft

Outcomes in Hispanic Kidney Transplant Recipients. Vu D, Tellez-Corrales E, Shah T, **Naraghi R**, Hutchinson IV, Min D. Clin Transplant. 2013 May-Jun;27(3):E308-15.

Gene Polymorphisms of UGT1A8, UGT1A9 and HNF-1 α are associated with Gastrointestinal Symptoms in Renal Transplant Recipients taking Mycophenolic acid.

Vu D, Tellez-Corrales E, Shah T, **Naraghi R**, Hutchinson IV, Min D. *Transpl Immunol.* 2013 Dec;29(1-4):155-61.

Association of interferon gamma gene polymorphisms with BK virus infection among Hispanic renal allograft recipients. Vu D, Shah T, Qazi, D, **Naraghi R**, Hutchinson IV, Min D. *Transplantation.* 2014 Mar 27;97(6):660-7.

Interferon-gamma gene polymorphism +874 A/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients.

Vu D, **Shah T**, Ansari J, Sakharkar P, Yasir Q, **Naraghi R**, Hutchinson I, Min D. *Transpl Infect Dis.* 2014 Oct;16(5):724-32.

“Long Term Follow-up of Tacrolimus Rescue Therapy for Renal Allograft Rejection.” Naraghi, R., Smith, D., Shapiro, R., Vivas, C., Gritsch, H., Scantlebury, V., McCauley, J., Randhawa, P., Demetris, A., McMichael, J., Fung, J., Starzl, T., Jordan, M. *Transplantation Proceedings* 29:310, 1997.

“Five Year Experience with Tacrolimus Rescue for Renal Allograft Rejection.” Jordan, M., Naraghi, R., Shapiro, R., Smith, D., Vivas, C., Scantlebury, V., Gritsch, H., McCauley, J., Randhawa, P., Demetris, A., McMichael, J., Fung, J., Starzl, T. *Transplantation Proceedings* 29:306, 1997.

“Evaluation of Computerized Tomography for Staging of Clinically Localized Adenocarcinoma of the Prostate.” Konety, B.R., **Naraghi, R.**, Gooding, W., O'Donnell, W.F., Bahnson, R.R. *Urologic Oncology* 2:14-19, 1996.

“Tacrolimus Rescue Therapy for Renal Transplant Rejection.” Jordan, M., **Naraghi, R.**, Shapiro, R., Smith, D., Vivas, C., Scantlebury, V., Gritsch, H., McCauley, J., Randhawa, P., Demetris, A., McMichael, J., Fung, J., Starzl, T. *Transplantation Proceedings* 28:4, 2119-2120, 1996.

“Routine Frozen Section of Pelvic Lymph Node Specimens Prior to Radical Retropubic Prostatectomy Is Unnecessary in Patients with Prostate Specific Antigen Levels Less Than 20 ng/ml.” **Naraghi, R.**, Becich, M., O'Donnell, W., Bahnson, R.R.

“Tacrolimus Rescue Therapy for Renal Allograft Rejection: Five Year Experience.” Jordan, M., **Naraghi, R.**, Shapiro, R., Smith, D., Vivas, C., Scantlebury, V., Gritsch, H., McCauley, J., Randhawa, P., Demetris, A., McMichael, J., Fung, J., Starzl, T. *Transplantation* 63:223-228, 1997.

BOOK CHAPTERS

Complications of Renal Transplantation Urologic Complications Vascular Complications

Robert Naraghi, M.D. Renal Transplantation. Editor: Ron Shapiro

Efficacy of Intravenous Immunoglobulin in the treatment of persistent BK viremia and BK Virus Nephropathy in renal transplant recipients. Shah T, Vu D, Naraghi R, Min D. Chapter 13, Clinical Transplant 2014.

CLINICAL RESEARCH EXPERIENCE

Principal Investigator:

Protocol 7163-CL-0108

Astellas Pharma Global Development

“A phase 2a, randomized, open-label, active control, multi-center study to assess the efficacy and safety of ASKP1240 in de novo kidney transplant recipients”

Protocol 8597-CL-0108

Astellas Pharma Global Development

“A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Dianxin) in de novo Kidney Transplant Recipients”

Protocol WV 25651

Genentech (Roche)

“A multicenter prospective cohort study to investigate if ganciclovir significantly affects spermatogenesis in adult male renal transplant recipients receiving up to 200 days valganciclovir vs. concurrent untreated matched controls”

Protocol QRK.006

Quark Pharmaceuticals

“Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation”

Protocol 0485-CL-U201

Astellas Pharma

“A phase 2, randomized, open-label, parallel group, multi-center study to assess the safety and efficacy of Alefacept in de novo kidney transplant recipients”

Protocol ML17225

Roche Pharmaceuticals

“An open-label, prospective, randomized, controlled, multi-center study assessing fixed dose vs. concentration controlled CellCept® regimens for patients following a single organ renal transplantation in combination with full dose and reduced dose calcineurin inhibitors.”

Protocol ML19199

Roche Pharmaceuticals

“Impact of pharmacogenetics on Mycophenolate Mofetil use.”

Sub-Investigator:

“Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following hmglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression”

“Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression”

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor”

Protocol 0624-201

ViroPharma Inc.

‘A Randomized Double-Blind Placebo-Controlled Pilot Study to Evaluate the Safety and Effect of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-Mediated Rejection in Recipients of Donor-Sensitized Kidney Transplants’

Protocol LCP-Tacro 3003

Veloxis Pharmaceuticals

‘Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacro (STRATO)’

Protocol IM103027

Bristol-Myers Squibb

“Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial—Extended Criteria Donors”

Protocol A3921021

Pfizer, Inc.

“A Multi-Center, Phase 2, Open-Label, Controlled, Extension Study for Stage 1 Subjects of Study A3921009 to Evaluate the Long-Term safety and efficacy of CP-690,550 versus Tacrolimus, when co-administered with Mycophenolate Mofetil in Renal Allograft Recipients”

Protocol A3921009

Pfizer, Inc.

“A 6-month, phase II, multi-center, randomized, open-label, comparative study of 2 dose levels of CP-690,550 administered concomitantly with IL-2 receptor antagonist induction therapy, Mycophenolate Mofetil and corticosteroids versus a Tacrolimus-based immunosuppressive regimen for the prevention of allograft rejection in de novo renal allograft recipients.”

Protocol ISA05-01

Isotechnika, Inc.

“A phase IIB, randomized, multi-center, open-label, concentration-controlled, safety study of ISA247 and Tacrolimus (Prograf®) in de novo renal transplant patients”

Protocol RAD001A2309

Novartis Pharmaceuticals

“A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican® in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral® versus 1.44 g Myfortic® with standard dose Neoral in de novo renal transplant recipients”

Protocol ML17140

Roche Pharmaceuticals

“An open label, randomized, multi-center study to evaluate the efficacy and safety of early calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on Mycophenolate Mofetil; MMF (CellCept®) and Sirolimus (Rapamune®)”

Protocol 02-0-158

Astellas Pharma US

“A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf® (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral® (cyclosporine)/MMF in de novo kidney transplant recipients”

Protocol 03-0-165

Astellas Pharma

“A phase II, randomized, open-label, parallel group, multicenter study to assess the safety and efficacy of Prograf®/FK778 and Prograf/MMF in de novo kidney transplant recipients.”

Protocol CERL080AUS51

Novartis Pharmaceuticals

“A 4-week, multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal (GI) safety and tolerability of Myfortic® and MMF (CellCept®) when administered in combination with calcineurin inhibitors (CNI) in renal transplant recipients experiencing gastrointestinal intolerance.”

Protocol CERL080AUS67

Novartis Pharmaceuticals

“A multicenter, randomized, double blind, double dummy, controlled study to assess the tolerability of an increased dose of Myfortic® after conversion from CellCept® in renal tra